Innoviva to acquire all outstanding shares of Entasis it does not already own for $2.20 per share in cash Price per share in cash represents a 50% premium to Entasis’ closing price of $1.47 per share ...
Entasis Therapeutics Holdings Inc. ETTX announced that it has signed a definitive merger agreement with Innoviva, Inc. INVA, wherein the latter will acquire all the outstanding shares it does not own ...
Holding company Innoviva is acquiring late-stage antibiotic biotech Entasis Therapeutics, a 2015 AstraZeneca spinout that just posted phase 3 results worthy of an FDA filing last year. Innoviva ...
Entasis Therapeutics steered its lead antibiotic candidate through late-stage clinical development with help from Innoviva, which has steadily invested in the company over the past two years and now ...
WALTHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel ...
Randomized, open label trial will assess the efficacy and safety of zoliflodacin versus a combination of azithromycin and ceftriaxone, the current standard of care 87 million new gonorrhea infections ...
WALTHAM, Mass.--(BUSINESS WIRE)--Entasis Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced initiation ...
WASHINGTON — Entasis Therapeutics announced at the World Anti-Microbial Resistance Congress that it has enrolled the first patient in a global phase 3 trial of oral zoliflodacin for the treatment of ...
Entasis Scores! The FDA's anti-infectives advisory board unanimously recommended approval of Entasis sulbactam-durlobactam for the treatment of hospital and ventilator-acquired pneumonia, caused by ...
The U.S. dithers, Europe ponders and the extinction of life-saving antibiotics continues apace. Here we go again. Entasis Therapeutics has been struggling in the public marketplace. There is certainly ...
Entasis Therapeutics has filed to raise up to $86 million through an IPO. The AstraZeneca spinout is seeking the money to fund a phase 3 trial of a drug to overcome bacterial resistance to ...
BURLINGAME, Calif. & WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback